Skip to main content
TipRanks
Go Ultimate75% OFF

Prothena (PRTA) AI Stock Analysis

687 Followers
PRTA

Prothena

(NASDAQ:PRTA)

Select Model
Rating:46Neutral
Price Target:$7.50â–¼(-8.09% Downside)
Action:reiterated
Date:11/06/26

The score is held down primarily by weak financial performance (ongoing losses and deteriorating negative free cash flow) and bearish technicals (price below key moving averages with negative MACD). Valuation is difficult to assess due to negative earnings and no dividend yield data, while a recent negative corporate event (PRX019 license termination) adds incremental program and funding-risk pressure despite continued potential from the moponetug partnership.

Positive Factors
Partnered Phase 3 PipelineTwo partnered programs have advanced to Phase 3, providing Prothena with late-stage clinical assets and validation from major pharmaceutical collaborators. Successful development could create durable milestone and royalty opportunities while reducing the burden of independently commercializing the products.
Negative Factors
Persistent Cash BurnNegative and deteriorating cash generation means Prothena remains dependent on its cash reserves, partner payments, or future financing to sustain development. Continued operating burn can reduce strategic flexibility and increase dilution or funding pressure if milestones arrive later than expected.

Prothena Key Performance Indicators (KPIs)

Revenue by SegmentShows how much revenue each business segment generates, highlighting which parts of the company are driving growth and which may need strategic adjustments.

$0.00$25.00M$50.00M$75.00M$100.00M$125.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Chart Insights

Revenue is clearly episodic—driven by partner milestone and license payments rather than recurring product sales—so pronounced spikes represent one‑off partner payments tied to clinical progress. Management highlighted meaningful near‑term upside (up to $105M in 2026 and larger multi‑billion potential milestones) but excludes these from base guidance, so cash runway and valuation hinge on milestone timing and partner decisions. Model Prothena as event‑driven: focus on upcoming partner catalysts and cash burn, not steady organic revenue growth.

Data provided by:The Fly

Prothena (PRTA) vs. SPDR S&P 500 ETF (SPY)

-30%-20%-10%0%10%20%PRTA-21.24%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$419.01M
Dividend Yield
―
Average Volume (3M)
466.33K
Price to Earnings (P/E)
-17.4
Beta (1Y)
0.92
Revenue Growth
347.44%
EPS Growth
91.00%
Country
US
Employees
67
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Prothena Business Overview & Revenue Model

Company Description

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized...

How the Company Makes Money

Prothena primarily generates revenue through collaboration and license arrangements rather than product sales, as it is a clinical-stage company. Under these agreements, Prothena can earn (1) upfront payments when a partnership is initiated or when a...

Prothena Earnings Call Summary

Earnings Call Date:Feb 19, 2026(Q4-2025)|% Change Since:-9.63%|Next Earnings Date:Feb 25, 2027
Earnings Call SentimentPositive

The call conveyed meaningful scientific and business progress — two partner programs advanced to Phase III, strong Phase II biomarker signals (40% reduction in a PD motor endpoint subset; 48% NT‑proBNP reduction for coramitug), introduction of a novel CYTOPE technology with encouraging preclinical TDP‑43 results, and a solid year‑end cash position ($308.4M). Material near‑term upside exists (up to $105M in 2026 milestones and ~ $3B in potential future milestones across partners). Offsetting risks include ARIA‑E safety concerns for PRX012 prompting re‑engineering, some non‑statistically significant secondary endpoints (6‑minute walk test), multi‑year timelines to Phase III primary completions (2029), continued net losses and burn, and reliance on partner decisions for key programs (PRX019). Overall, positives — pipeline advancement, strong partner validation, and a healthy cash balance — outweigh the operational and timing risks.

Positive Updates

Two Partner Programs Advanced to Phase III
Roche advanced prasinezumab into the Phase III PARAISO trial (≈900 participants; primary completion expected in 2029). Novo Nordisk advanced coramitug into the Phase III CLEOPATTRA trial (≈1,280 patients; primary completion expected in 2029).

Negative Updates

ARIA‑E and Safety Profile Concerns for PRX012
PRX012 ASCENT reported ARIA‑E rates described as 'noncompetitive' relative to FDA‑approved anti‑Aβ antibodies, prompting a strategic pivot to a PRX012‑transferrin receptor (TfR) program to try to improve the ARIA profile.

Company Guidance

Prothena's 2026 guidance calls for full‑year net cash used in operating and investing activities of $50–55 million, an estimated net loss of $67–72 million (which includes about $24 million of noncash share‑based compensation), and an expected year‑end cash, cash equivalents and restricted cash balance of approximately $255 million at the midpoint; this guidance does not include up to $105 million of potential aggregate clinical milestone payments from partners in 2026. For context, Prothena closed 2025 with $308.4 million in cash (as of Dec 31, 2025), reported 2025 net cash used in operating and investing activities of $163.7 million (favorable to prior guidance of $170–178 million), a 2025 net loss of $244.1 million (in line with guidance of $240–248 million), had 53.8 million ordinary shares outstanding as of Feb 12, 2026, and a simple capital structure with zero debt.

Prothena Financial Statement Overview

Summary

Overall fundamentals are pressured by multi-year operating losses and persistent negative free cash flow (TTM OCF about -$31.4M; TTM FCF about -$32.2M, worsening ~47% vs prior period). The balance sheet is a relative strength with very low leverage (TTM debt-to-equity ~0.02), but the equity base has shrunk materially and ROE is negative, underscoring ongoing burn and dilution risk. Revenue remains volatile and recently contracted (TTM down ~3.3%), consistent with a higher-risk, milestone-driven biotech profile.

Income Statement

24Negative

Balance Sheet

68Positive

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue52.73M9.68M135.16M91.37M53.91M200.58M
Gross Profit50.88M5.98M135.16M91.37M53.91M200.58M
EBITDA-23.35M-199.93M-128.04M-159.55M-124.86M73.04M
Net Income-23.96M-244.09M-122.31M-147.03M-116.95M66.97M
Balance Sheet
Total Assets283.52M326.80M547.11M696.38M758.03M609.37M
Cash, Cash Equivalents and Short-Term Investments271.37M307.53M471.39M618.83M710.41M579.09M
Total Debt6.26M13.86M10.84M11.84M6.47M12.33M
Total Liabilities14.68M46.33M60.18M135.02M135.99M143.32M
Stockholders Equity268.84M280.47M486.93M561.37M622.04M466.04M
Cash Flow
Free Cash Flow-32.17M-163.72M-150.35M-136.72M-109.28M92.03M
Operating Cash Flow-31.45M-163.58M-150.05M-133.91M-108.82M92.61M
Investing Cash Flow-725.00K-138.00K-298.00K-2.77M-464.00K-575.00K
Financing Cash Flow-27.30M-139.00K1.55M45.10M241.46M190.33M

Prothena Technical Analysis

Technical Analysis SentimentNegative
Last Price8.16

Price Trends

50DMA8.54Negative
100DMA8.80Negative
200DMA9.17Negative

Market Momentum

MACD-0.05Positive
RSI45.77Neutral
STOCH53.65Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRTA, the sentiment is Negative. The current price of 8.16 is below the 20-day moving average (MA) of 8.42, below the 50-day MA of 8.54, and below the 200-day MA of 9.17, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 45.77 is Neutral, neither overbought nor oversold. The STOCH value of 53.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PRTA.

Prothena Risk Analysis

Prothena disclosed 62 risk factors in its most recent earnings report. Prothena reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Prothena Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

PRTA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ALECALEC58Neutral$378.15M7.26112.21%―151.23%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AVXLAVXL46Neutral$86.53M-6.35-11.43%――73.28%
PRTAPRTA46Neutral$419.01M-17.36-8.34%―347.44%91.00%
ACIUACIU45Neutral$216.78M-4.46-104.05%―384.77%38.30%
IKTIKT40Underperform$213.21M-3.41-40.53%――28.48%
ABOSABOS38Underperform$15.48M-0.14-166.49%――29.92%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%PRTAAVXLACIUALECIKTABOSDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
PRTA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
PRTAProthena Corporation8.16-2.09-20.39%
AVXLAnavex Life Sciences0.93-2.65-73.94%
ACIUAC Immune2.13-0.97-31.29%
ALECAlector2.541.30104.84%
IKTInhibikase Therapeutics, Inc.1.520.000.00%
ABOSAcumen Pharmaceuticals, Inc.0.21-1.37-86.46%

Prothena Corporate Events

Business Operations and Strategy

Prothena Faces PRX019 License Termination by Bristol Myers

Negative
Oct 29, 2026

On October 28, 2026, Bristol Myers Squibb notified Prothena that it would not advance PRX019 further in clinical development, leading to the termination of their exclusive global license agreement for the candidate effective January 28, 2027. PRX019...

Business Operations and StrategyExecutive/Board Changes

Prothena Chief Development Officer Resigns for Partner Role

Neutral
Oct 2, 2026

On October 2, 2026, Prothena announced that its Chief Development Officer, Chad J. Swanson, Ph.D., has resigned effective October 9, 2026, to take a role with one of the company’s strategic partners. In his new position, Dr. Swanson will assume a lea...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 06, 2026